The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization

Virology

Volumn 421, Issue 2, 2011, Pages 235-244

  Lovelace, Erica ^a   Xu, Hengyu ^a   Blish, Catherine A ^a   Strong, Roland ^a   Overbaugh, Julie ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Antibody binding; Antibody neutralization; Envelope; Gp41; HIV 1

Indexed keywords

ALANINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; ISOLEUCINE; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; THREONINE; VALINE;

AMINO ACID SUBSTITUTION; ANTIGEN BINDING; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; SURFACE PLASMON RESONANCE; VIRION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; HEK293 CELLS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ANALYSIS, PROTEIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80355131958     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.09.032     Document Type: Article

References (60)

1. Back N.K., Smit L., Schutten M., Nara P.L., Tersmette M., Goudsmit J. Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J. Virol. 1993, 67:6897-6902.
2. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 2004, 78:13232-13252.
3. Blay W.M., Kasprzyk T., Misher L., Richardson B.A., Haigwood N.L. Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses. J. Virol. 2007, 81:13037-13049.
4. Blish C.A., Nedellec R., Mandaliya K., Mosier D.E., Overbaugh J. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 2007, 21:693-702.
5. Blish C.A., Nguyen M.A., Overbaugh J. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med. 2008, 5:e9.
6. Blish C.A., Jalalian-Lechak Z., Rainwater S., Nguyen M.-A., Dogan O.C., Overbaugh J. Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1. J. Virol. 2009, 83:7783-7788.
7. Blish C.A., Sather D.N., Sellhorn G., Stamatatos L., Sun Y., Srivastava I., Barnett S.W., Cleveland B., Overbaugh J., Hu S.L. Comparative immunogenicity of subtype a human immunodeficiency virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes. J. Virol. 2010, 84:2573-2584.
8. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027.
9. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 2004, 5:233-236.
10. Burton D.R., Stanfield R.L., Wilson I.A. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:14943-14948.
11. Cardoso R.M., Zwick M.B., Stanfield R.L., Kunert R., Binley J.M., Katinger H., Burton D.R., Wilson I.A. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005, 22:163-173.
12. Cardoso R.M., Brunel F.M., Ferguson S., Zwick M., Burton D.R., Dawson P.E., Wilson I.A. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J. Mol. Biol. 2007, 365:1533-1544.
13. Cavacini L., Posner M. Native HIV type 1 virion surface structures: relationships between antibody binding and neutralization or lessons from the viral capture assay. AIDS Res. Hum. Retroviruses 2004, 20:435-441.
14. de Rosny E., Vassell R., Jiang S., Kunert R., Weiss C.D. Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J. Virol. 2004, 78:2627-2631.
15. Dey A.K., David K.B., Lu M., Moore J.P. Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology 2009, 385:275-281.
16. Doria-Rose N.A., Learn G.H., Rodrigo A.G., Nickle D.C., Li F., Mahalanabis M., Hensel M.T., McLaughlin S., Edmonson P.F., Montefiori D., Barnett S.W., Haigwood N.L., Mullins J.I. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J. Virol. 2005, 79:11214-11224.
17. Fouts T.R., Binley J.M., Trkola A., Robinson J.E., Moore J.P. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. Virology 1997, 71:2779-2785.
18. Herrera C., Klasse P.J., Michael E., Kake S., Barnes K., Kibler C.W., Campbell-Gardener L., Si Z., Sodroski J., Moore J.P., Beddows S. The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology 2005, 338:154-172.
19. Hu S.L. Non-human primate models for AIDS vaccine research. Curr. Drug Targets Infect. Disord. 2005, 5:193-201.
20. Julien J.P., Huarte N., Maeso R., Taneva S.G., Cunningham A., Nieva J.L., Pai E.F. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. J. Virol. 2010, 84:4136-4147.
21. Klasse P.J., McKeating J.A., Schutten M., Reitz M.S., Robert-Guroff M. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site. Virology 1993, 196:332-337.
22. Leaman D.P., Kinkead H., Zwick M.B. In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. J. Virol. 2010, 84:3382-3395.
23. Long E.M., Rainwater S.M.J., Lavreys L., Mandaliya K., Overbaugh J. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res. Hum. Retroviruses 2002, 18:567-576.
24. Mascola J.R. Defining the protective antibody response for HIV-1. Curr. Mol. Med. 2003, 3:209-216.
25. Moore P.L., Crooks E.T., Porter L., Zhu P., Cayanan C.S., Grise H., Corcoran P., Zwick M.B., Franti M., Morris L., Roux K.H., Burton D.R., Binley J.M. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 2006, 80:2515-2528.
26. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993, 67:6642-6647.
27. Myszka D.G. Improving biosensor analysis. J. Mol. Recognit. 1999, 12:279-284.
28. Nyambi P.N., Nadas A., Mbah H.A., Burda S., Williams C., Gorny M.K., Zolla-Pazner S. Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J. Virol. 2000, 74:10670-10680.
29. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., Kwong P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 2004, 78:10724-10737.
30. O'rourke S.M., Schweighardt B., Scott W.G., Wrin T., Fonseca D.P.A.J., Sinangil F., Berman P.W. Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. J. Virol. 2009, 83:7728-7738.
31. Pancera M., Wyatt R. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 2005, 332:145-156.
32. Park E.J., Vujcic L.K., Anand R., Theodore T.S., Quinnan G.V. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes. J. Virol. 1998, 72:7099-7107.
33. Park E.J., Gorny M.K., Zolla-Pazner S., Quinnan G.V. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex. J. Virol. 2000, 74:4183-4191.
34. Parren P.W., Mondor I., Naniche D., Ditzel H.J., Klasse P.J., Burton D.R., Sattentau Q.J. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J. Virol. 1998, 72:3512-3519.
35. Parren P.W., Wang M., Trkola A., Binley J.M., Purtscher M., Katinger H., Moore J.P., Burton D.R. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72:10270-10274.
36. Phogat S., Svehla K., Tang M., Spadaccini A., Muller J., Mascola J., Berkower I., Wyatt R. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology 2008, 373:72-84.
37. Pineda M.J., Orton B.R., Overbaugh J. A TRIM5alpha-independent post-entry restriction to HIV-1 infection of macaque cells that is dependent on the path of entry. Virology 2007, 363:310-318.
38. Poignard P., Moulard M., Golez E., Vivona V., Franti M., Venturini S., Wang M., Parren P.W., Burton D.R. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 2003, 77:353-365.
39. Poss M., Overbaugh J. Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. J. Virol. 1999, 73:5255-5264.
40. Reitz M.S., Wilson C., Naugle C., Gallo R.C., Robert-Guroff M. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 1988, 54:57-63.
41. Roben P., Moore J.P., Thali M., Sodroski J., Barbas C.F.r., Burton D.R. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 1994, 68:4821-4828.
42. Sattentau Q.J., Moore J.P. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 1995, 182:185-196.
43. Saunders C.J., McCaffrey R.A., Zharkikh I., Kraft Z., Malenbaum S.E., Burke B., Cheng-Mayer C., Stamatatos L. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J. Virol. 2005, 79:9069-9080.
44. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Olivera T.Y.K., Pietzsch J., Fenyo D., Abadir A., Velinzon K., Hurley A., Myung S., Boulad F., Poignard P., Burton D., Pereyra F., Ho D.D., Walker B.D., Seaman M.S., Bjorkman P.J., Chait B.T., Nussenzweig M.C. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding. Science 2011, 333(6049):1633-1637. [Electronic publication ahead of print, 2011 Jul 14].
45. Shen X., Dennison S.M., Liu P., Gao F., Jaeger F., Montefiori D.C., Verkoczy L., Haynes B.F., Alam S.M., Tomaras G.D. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:5972-5977.
46. Stamatatos L., Cheng-Mayer C. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. J. Virol. 1995, 69:6191-6198.
47. Sullivan N., Sun Y., Li J., Hofmann W., Sodroski J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 1995, 69:4413-4422.
48. Thali M., Charles M., Furman C., Cavacini L., Posner M., Robinson J., Sodroski J. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change. J. Virol. 1994, 68:674-680.
49. Vodicka M.A., Goh W.C., Wu L.I., Rogel M.E., Bartz S.R., Schweickart V.L., Raport C.J., Emerman M. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 1997, 233:193-198.
50. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., Lehrman J.K., Priddy F.H., Olsen O.A., Frey S.M., Hammond P.W., Kaminsky S., Zamb T., Moyle M., Koff W.C., Poignard P., Burton D.R. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
51. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.P., Wang S.K., Ramos A., Chan-Hui P.Y., Moyle M., Mitcham J.L., Hammond P.W., Olsen O.A., Phung P., Fling S., Wong C.H., Phogat S., Wrin T., Simek M.D., Koff P.G., Wilson W.C., Burton I.A., Poignard D.R., P. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477(7365):466-470. Principal Investigators, doi:10.1038/nature10373. [Electronic publication ahead of print].
52. Wilson C., Reitz M.S., Aldrich K., Klasse P.J., Blomberg J., Gallo R.C., Robert-Guroff M. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. J. Virol. 1990, 64:3240-3248.
53. Wu X., Parast A.B., Richardson B.A., Nduati R., John-Stewart G., Mbori-Ngacha D., Rainwater S.M., Overbaugh J. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J. Virol. 2006, 80:835-844.
54. Wu X., Zhou T., O'Dell S., Wyatt R.T., Kwong P.D., Mascola J.R. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J. Virol. 2009, 83:10892-10907.
55. Wu X., Yang Z.-Y., Li Y., Hogerkorp C.-M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., Longo N.S., McKee K., O'Dell S., Louder M.K., Wycuff D.L., Feng Y., Nason M., Doria-Rose N., Connors M., Kwong P.D., Roederer M., Wyatt R.T., Nabel G.J., Mascola J.R. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
56. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., Chen X., Longo N.S., Louder M., McKee K., O'Dell S., Perfetto S., Schmidt S.D., Shi W., Wu L., Yang Y., Yang Z.Y., Yang Z., Zhang Z., Bonsignori M., Crump J.A., Kapiga S.H., Sam N.E., Haynes B.F., Simek M., Burton D.R., Koff W.C., Doria-Rose N., Connors M., Mullikin J.C., Nabel G.J., Roederer M., Shapiro L., Kwong P.D., Mascola J.R. Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing. Science 2010, 333(6049):1593-1602. [Electronic publication ahead of print, 2011 Aug 11].
57. Xu H., Song L., Kim M., Holmes M.A., Kraft Z., Sellhorn G., Reinherz E.L., Stamatatos L., Strong R.K. Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity. J. Virol. 2010, 84:1076-1088.
58. Zolla-Pazner S., Cardozo T. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat. Rev. Immunol. 2010, 10:527-535.
59. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001, 75:10892-10905.
60. Zwick M.B., Jensen R., Church S., Wang M., Stiegler G., Kunert R., Katinger H., Burton D.R. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 2005, 79:1252-1261.